Gilead Sciences's office in Israel: Haharash, Hod Hasharon

Business Address: POB 6090, 4 Haharash, Hod Hasharon 4524075

E-mail: Safety_FC@gilead.com,   Complaints.Israel@gilead.com

Web: https://www.gileadisrael.co.il, https://sideeffects.health.gov.il

Type Public
Traded as
  • Nasdaq: GILD
  • NASDAQ Biotechnology Component
  • NASDAQ-100 Component
  • S&P 100 Component
  • S&P 500 Component
Industry
  • Pharmaceutics
  • Biotechnology
Founded June 22, 1987 (1987-06-22)
Headquarters Foster City, California, United States
Area served Worldwide
Key people
  • Daniel O'Day
    (CEO and Chairman)
  • Andrew Dickinson
    (CFO)
  • Tomáš Cihlář
    (Vice president, and
    Senior Director, Biology)
Products
  • AmBisome
  • Atripla
  • Biktarvy
  • Complera
  • Cayston
  • Descovy
  • Emtriva
  • Epclusa
  • Genvoya
  • Harvoni
  • Hepsera
  • Letairis
  • Lexiscan
  • Macugen
  • Odefsey
  • Ranexa
  • Sovaldi
  • Stribild
  • Tamiflu
  • Truvada
  • Tybost
  • Veklury
  • Vemlidy
  • Viread
  • Vosevi
  • Yescarta
  • Zydelig
Revenue Increase US$27.31 billion (2021)
Operating income Increase US$9.92 billion (2021)
Net income Increase US$6.23 billion (2021)
Total assets Decrease US$67.95 billion (2021)
Total equity Increase US$21.06 billion (2021)
Number of employees Increase 14,400 (2021)

At Gilead, we’re committed to creating possible. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases. Through bold and transformative science, we’re creating possibilities that have the potential to become the next generation of life-changing medicines. Our ambition is evident in our mission. Because the impossible is not impossible. It’s what’s next.

Gilead Sciences's locations around the world

Abonnere